, Tracking Stock Market Picks
Enter Symbol:
Rating: ALKS
Buy $59

Alkermes, Inc. (NASDAQ: ALKS) reiterated to Buy with price target $59 by Mizuho

Thursday,  Jul 31, 2014  12:00 AM ET by Kristen Bailey

Alkermes, Inc. (NASDAQ: ALKS)
rated Buy with price target $59 by Mizuho.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy